SCA
ESPR

Snowden Capital Advisors’s Esperion Therapeutics ESPR Stock Holding History

Snowden Capital Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$1K – 1348
2021
Q4 		$1K Buy
+200
New +$1.6K ﹤0.01% 1942

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Snowden Capital Advisors's ESPR Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 200 shares — an estimated $1K sold.

Snowden Capital Advisors first reported a position in ESPR in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 200 Esperion Therapeutics shares in Q1 2022, an estimated $1K.
  • Snowden Capital Advisors first reported a position in Esperion Therapeutics in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Esperion Therapeutics position peaked at $1K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.